DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20171970

Effects of letrozole on patients with symptomatic leiomyoma in the reproductive age women

Ranjana Prakash, Sushma Pandey, Indu Chawla

Abstract


Background: Uterine leiomyoma is a common indication for hysterectomy in India. An effective medical treatment option may reduce hysterectomy associated morbidity. This study was undertaken to evaluate the effect of the Letrozole on patients with symptomatic leiomyoma in the reproductive age women.

Methods: Prospective interventional study was conducted on 50 women between 30-45 years of age with menstrual or pressure symptoms on the bowel or urinary system, and having no. Of myoma ≤4 and size of single myoma ≥2 cms in diameter. They received tablet letrozole 5mg/day for 3 month, and effect of the drug on myoma volume and symptomatology were studied. Beside these, effects on uterine volume, ovarian volume, endometrial thickness and side effects of letrozole of any were also studied.

Results: Average reduction of myoma volume by 47.68% and uterine volume by 19.58% was seen. Haemoglobin concentration was significantly higher at the end of study. It increased from 9.56g/dl to 10.76g/dl and overall improvement in symptomatology score was observed. Ovarian volume increased significantly from baseline mean volume of 8.18±0.51cm³ to 19.3±0.84cm³ and no significant change in endometrial thickness was observed at the end of 3 month. Sweating, hot flushes, nausea and vomiting were the main adverse effects observed and were self limiting.

Conclusions: Letrozole, the aromatase inhibitor resulted in significant volume reduction of the uterus-leiomyoma structure and was effective in controlling the more frequent symptoms of this disorder with fewer side effects.


Keywords


Aromatase inhibitor, Letrozole, Medical treatment, Myoma, Uterus

Full Text:

PDF

References


Adamson GD. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 1992;166:746-51.

Carlson KJ, Nichols DH, Schiff I. Indications of hysterectomy. N Engl J Med. 1993;328:856-60.

Smart OC, Hindley JT, Regan L and Gedroyc WG. Gonadotrophin-releasing hormone and magnetic-resonance guided ultrasound surgery for uterine leiomyomata. Obstet Gynecol. 2006;108:49-54.

Delco V la Marca A, Margante G. Short term treatment of uterine fibromyomas with danazole gynecol. Obstet Invest.1999;47:258-62.

Stovall TG, Summit RL, Jr, Washburn SA, Ling FW. Gonadotropin- releasing hormone agonist use before hysterectomy. Am J Obstet Gynecol. 1994;170:1744-51.

Lethaby A, Vollenhoven B, Sowter M. Preoperative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001:CD000547.

Pron G, Cohen M, Soucie J, Garvin G, Vanderburgh L, Bell S. The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril. 2003;79:112-9.

Gurates B, Parmaksiz C, Kilic G, Celik H, Kumru S, and Simsek M. Treatment of symptomatic uterine leiomyoma with letrozole. Reprod Biomed Online. 2008;17:569-74.

Bulun SE, Imir G, Utsunomiya H, Thung S, Gurates B, and Tamura M. Aromatase in endometriosis and uterine leiomyomata. J Steroid Biochem Mol Biol. 2005;95:57-62.

Andersen J, DyReys VM, Barbieri RL, Cochman DM, Miksicek RJ. Leiomyoma primary cultures have elevated transcriptional response to Invest 1995;2:542-51.

Karaer O, Oruc S and Koyuncu FM: Aromatase inhibitors: possible future applications. Acta Obstet Gynecol Scand. 2004;83:699-706.

Hilario SG, Bozzini N, Borsari R, Baracat EC. Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenpausal patients. Fertil Steril. 2009;91(1):240-3.

Weeks AD, Duffy SR and Walker JJ. Uterine ultrasonographic changes with gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 1999;180:8-13.

Sumitani H, Shozu M, Segawa T, Murakami K,Yang H, Shimada K, etal. In situ oestrogen synthesized by aromatase p450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinol. 2000;141:3852-60.

Shozu M, Murakami K, Inoue U. Aromatase and leiomyoma of the uterus. Semin S Reprod Med. 2004;22:55-61.

Shozu M, Murakami K, Segawa T, Kesal T, Inoue M. successful treatment of a symptomatic uterine leiomyoma in a premenopausal women with a non steroidal aromatase inhibitor. Fertil Steril. 2003:79:628-31.

Parsanezhad ME, Azmoon M, Alborzis S, etal. A randomized controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin- releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status. Fertil Steril. 2010;74:192-8.

Sinha S, Kaseta J, Santner SJ, Demers LM, Bremmer WJ, Santen RJ. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res Treat. 1998;48:45-51.

Yosry LM, Hamed E, El Naggar AA. The effect of aromatase inhibitor on uterine leiomyoma volume by ultrasonography and colour Doppler. J Am Sci. 2012;8(8):1031-4.

Kumru S, Yildiz AA, Yilmaz B, Sandal S, Gurates B. Effects of aromatase inhibitors letrozole and anastrazole on bone metabolism and steroid hormone levels in intact female rats. Gynecol Endocrinol. 2007;23:556-61.

Mitwally MF, Casper RF. Use of aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305-9.